HIV Sample Clauses

HIV. The parties understand that HIV is a highly communicable disease that could be life threatening if proper safety procedures are not followed. Facilities and officers will have available to them, at no cost, high quality HIV germicidal available for immediate use.

HIV. IF unable to obtain HIV status or patient is known HIV positive status, drugs for prevention need to be started within 3 hours. a) If PEP INDICATED- no HIV status attainable, or HIV positive b) INITIAL VISIT: i) MD and student determine if PEP will be started ii) Baseline labs iii) Begin PEP starter kit if have not already. iv) Discuss PEP regimen. v) Prescribe remaining PEP regimen.

HIV. The Parties acknowledge that all milestones payments to JT required under the Original Agreement have been paid and no further amounts are due. Any such payments were and shall be [*] under this Agreement.

HIV. AIDS and combating pandemics The company agrees to apply the principles of the "ILO code of practice on HIV/AIDS and the world of work" and implement employee information campaigns on this epidemic (and any other local pandemic) in at-risk countries: - To put in place awareness and education programmes aimed at employees in their workplace concerning prevention and handling of the sick, notably those with HIV/AIDS - To eliminate all discrimination, particularly in the hiring process, and stigmatisation with regard to the sick - To protect the rights of employees affected (respect for private life and confidentiality, rights and access to services and upholding of the employee relationship) - To provide employees with all the information, help and advice available (support with voluntary and confidential screening, guidance towards specialist internal or external advice and services, aid programmes, etc.) Information actions also apply to service providers and/or subcontractors working on the premises or sites of the company and may also apply to the families of employees when sickness has a major impact on the family. The Group commits its service providers and/or subcontractors to carry out information actions with their employees.

HIV. 2.5.1 There were 94,397 people living with diagnosed HIV infection and accessing care in England in 2022, a rise of 3% from 91,368 in 2021. The number of HIV diagnoses in England rose by 22% from 3,118 in 2021 to 3,805 in 2022. Most of this increase is attributable to people previously diagnosed abroad, a 69% increase from 805 in 2021 to 1,361 in 2022. These infections were likely acquired abroad and therefore do not reflect a rise in transmission in England but highlights the increase in people accessing treatment in England. 2.5.2 BHIVA is accredited by the National Institute for Health and Clinical Excellence (NICE) to produce the UK national guidelines on best clinical practice for the treatment and management of adults with HIV infection on antiretroviral therapy (ART). 2.5.3 The Paediatric Network for the treatment of AIDS (Penta), a scientific organisation dedicated to paediatric research, remain the responsible organisation for producing the guidelines for children and adolescents in the European region. 2.5.4 Since 2019, NICE have been responsible for the technology appraisals of all HIV treatments. 2.5.5 Until the publication of national prescribing guidelines in 2022, choice of ART had been informed by national best practice guidelines or regional guidance where they existed. 2.5.6 There are currently 22 molecules in the HIV market which cover the 4 drug classes required to suppress the virus, they are combined in several ways to create different formulations. Over the years these molecules have been combined to create a number of different treatment regimens. The use of each regimen is determined by a number of ‘usability’ criteria, i.e. what regimen is suitable/preferred in patients with other conditions e.g. TB, Hep C, osteoporosis, mental health etc. 2.5.7 Children over the age of 12 can use the same treatment regimens as for adults where licensed/indicated. Infants and paediatrics have separate treatment regimens due to the need to administer a dose according to their age and weight. 2.5.8 Current treatment regimens for adults and adolescents include NHSE & BHIVA recommended treatments.

HIV. The latest HIV data highlight the reality of multiple epidemics in Somalia with generalized features in and there is a concentrated and low level epidemic in South Central.

HIV vertical transmission of HIV is now rare in the UK following the widespread implementation of antenatal screening, antiretroviral treatment in pregnancy and avoidance of breastfeeding • the risk of vertical HIV transmission in an untreated woman in pregnancy is around 25%. However, with early diagnosis, effective treatment and subsequent viral suppression, the risk of transmission is now very low (under 0.5%) • babies born to mothers with hepatitis B are at higher chance of acquiring HBV • the risk of transmission depends on the status of the maternal infection • without intervention, 70 to 90% of mothers who have higher infectivity will pass the infection to their baby compared to a 10% risk for mothers who have lower infectivity • perinatal transmission can result in an acute or chronic infection, but babies have a much higher chance of being chronically infected • without vaccination, 95% will have a sub-clinical infection (rather than acute hepatitis) and many become chronic carriers for life • the development of chronic infection after perinatal transmission can be prevented in over 90% of cases by timely vaccination (hepatitis B vaccine +/- hepatitis B immunoglobulin (HBIG)).

HIV. Gilead shall make the following milestone payments to JT based on achievement of the following regulatory and Commercialization milestone events with respect to HIV for Products in the Gilead Territory as set forth in this Section 8.2. Gilead shall notify JT promptly in writing after first achievement of each of the milestone events listed below, and Gilead shall pay to JT the amounts set forth below. Such report and payment may occur together, at the same time, within [*] days of Gilead’s achievement of the relevant milestone event for a Product. Each milestone payment by Gilead to JT hereunder shall be payable only once, regardless of the number of times achieved with one Product or multiple Products for use with respect to HIV. Each such payment shall be [*] under this Agreement. For clarification, the milestone payments hereunder shall be paid to JT from Gilead and/or its Affiliates from the United States and/or up to two (2) other jurisdictions for which no withholding tax is applicable. 1. First [*] (the “First Event”) $ [*] million

HIV. Since HIV transmission most often occurs at the vaginal and rectal mucosa, studies focusing on the role of the microbiota at theses surfaces have become of wide interest and are discussed below. Lactic acid-producing bacteria primarily dominate the vaginal mucosa, and microbiota composition at this surface is less diverse than in the gut. Lowered diversity, however, is associated with greater female reproductive tract health (114). Unlike gut microbiota, very few studies have examined how vaginal microbiota influences immunity at the vagina. Exposure of the vagina to lactic acid-producing bacteria strains was found to decrease inflammation at the lower vaginal epithelium (115, 116). Reducing inflammation would likely decrease the numbers and migration of the primary targets of HIV, including macrophages, DCs, and CD4 T cells, and thus, lower susceptibility to infection at the vaginal mucosa. Some investigators have proposed that vaginal microbiota may regulate susceptibility to HIV infection by making antipathogen products that could directly inhibit virus viability. Indeed, studies have shown that lactic acid, hydrogen peroxide, and bacteriocins made by lactic acid-producing bacteria may prevent infection at the vaginal mucosa (117-119). Furthermore, vaginal microbiota has been shown to make lectins, a group of carbohydrate-binding proteins, which adheres to the surface of HIV, and as a result, lectins may prevent infection of macrophages and DCs by competitively binding to free HIV (120). Microbiota along the gastrointestinal tract has been studied after HIV infection; unfortunately little is known about how microbiota influences initial HIV infectivity. After HIV infection, gut microbiota dramatically changes with higher numbers of pathogens present than beneficial microorganisms (121-123). Furthermore, more microbial translocation from the gut to the blood is observed in HIV-infected individuals; this translocation positively correlates and contributes to chronic inflammation and worsening of many infection-related conditions (124).

HIV. As a program designed to support PLHIV and people affected by HIV, it follows that the virus has personally impacted the majority of YFL participants. The narrative data collected for this study show that experiences and perceptions of HIV influence participants’ lives and interactions with others. Naturally, the degree to which HIV influences an individual’s life depends upon one’s personal connection to HIV (living with HIV, HIV advocate, friend/partner is HIV positive, no personal connection to HIV). But within the context of the YFL community, findings show that even HIV negative participants who do not feel at risk for HIV infection have been affected by HIV through education and media exposure that influence their attitudes and behaviors.